Product Description
BIIB022 is a non-glycosylated human IgG4 monoclonal antibody (mAb) with specificity for IGF-1R.
Mechanisms of Action: IGF Blocker
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biogen
Company Location: Eastern America
Company Founding Year: 1978
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hepatocellular Carcinoma|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00970580 |
212-LC-101 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2011-09-01 |
2019-03-19 |
Treatments |
|
NCT00956436 |
212HC201 | P1 |
Completed |
Hepatocellular Carcinoma |
2011-04-01 |
2019-03-18 |
Treatments |
|
NCT00555724 |
212ST101 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2010-04-01 |
2019-03-22 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|